ArticleCells2019
Differences between the Proliferative Effects of Human Platelet Lysate and Fetal Bovine Serum on Human Adipose-Derived Stem Cells.
Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Evaluation of the hydrogels Matrigel, Biogelx, PLTMAx and GelMA in the generation of minilungs from human embryonic stem cells (hESC).Stem cell research & therapy · 2026Article
- The Use of Human Platelet Lysate (hPL) Enables 3D Cultivation of ADSCs Derived From Human Breast Tissue.Stem cells international · 2026Article
- Molecular Insights into the Superiority of Platelet Lysate over FBS for hASC Expansion and Wound Healing.Cells · 2025Article
- Article
- Predominant control of PDGF/PDGF receptor signaling in the migration and proliferation of human adipose‑derived stem cells under culture conditions with a combination of growth factors.Experimental and therapeutic medicine · 2024Article
- Optimized Decellularization Protocol for Large Peripheral Nerve Segments: Towards Personalized Nerve Bioengineering.Bioengineering (Basel, Switzerland) · 2022Article
- Platelet Derivatives and the Immunomodulation of Wound Healing.International journal of molecular sciences · 2022Review
- Enhancing therapeutic efficacy of human adipose-derived stem cells by modulating photoreceptor expression for advanced wound healing.Stem cell research & therapy · 2022Article
- Hydrogel supplemented with human platelet lysate enhances multi-lineage differentiation of mesenchymal stem cells.Journal of nanobiotechnology · 2022Article
- Article
- Posology and Serum-/Xeno-Free Engineered Adipose Stromal Cells Cell Sheets.Frontiers in cell and developmental biology · 2022Article
- Human nasal olfactory stem cells, purified as advanced therapy medicinal products, improve neuronal differentiation.Frontiers in neuroscience · 2022Article
- Adipose-derived stem cell secretome as a cell-free product for cutaneous wound healing.3 Biotech · 2021Review
- Towards Physiologic Culture Approaches to Improve Standard Cultivation of Mesenchymal Stem Cells.Cells · 2021Review
- Article
- Adipose-Derived Stromal/Stem Cells.Cells · 2020Article
- Review
- Biological Considerations in Scaling Up Therapeutic Cell Manufacturing.Frontiers in pharmacology · 2020Review
- Influence of Human Platelet Lysate on Extracellular Matrix Deposition and Cellular Characteristics in Adipose-Derived Stem Cell Sheets.Frontiers in cell and developmental biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, human adipose-derived stem cells (hASCs) were discovered in the human subcutaneous adipose tissue. PLTMax Human Platelet Lysate (PLTMax), a supplement refined from human platelets, has been reported to have proliferative effects on bone marrow mesenchymal stem cells. The proliferative effects of PLTMax on ASCs were investigated in this study.
methodsThe ASCs in DMEM (serum-free), DMEM+PLTMax (1%, 2%, 5%, and 10%), and DMEM+FBS (10%) were cultivated for two, five, and seven days. The cell growth rate was examined, BrdU incorporation, and the cell cycle and Ki-67 immunostaining were performed. The cell growth rate was investigated when each inhibitor (PD98059, SP600125, SB203580, and LY294002) was added and phosphorylation of ERK1/2, JNK, p38, and Akt were examined by western blotting. The cell surface marker of hASCs was also analyzed.
resultsThe cells in the PLTMax (5%) group showed significantly more proliferation compared to the cells in control (serum-free) and FBS (10%) groups, and a significant increase in the number of cells in the S phase and G2/M phase. The number of Ki-67 positive cells increased significantly in the DMEM+ PLTMax (5%) and the FBS (10%) groups. The addition of inhibitors PD98059, SP600125, SB203580, and LY294002 decreased the proliferative effects of PLTMax on ASCs. Phosphorylation of ERK1/2, JNK, p38, and Akt was observed in both the PLTMax (5%) and the FBS (10%) groups.
conclusionsFor human adipose stem cells, 5% PLTMax was the optimum concentration, which showed a significantly higher proliferative effect than 10% FBS. PLTMax is a useful medium additive, which can substitute FBS. The proliferative effects of PLTMax are suggested to function via multiple signaling pathways, similar to FBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.